Pre-market hot trades in US stocks: Mobile-Health Network Solutions up 31.58% in pre-market; Inno up 29.46% in pre-market

Tracking Unusual Activity
2025.11.26 09:01
portai
I'm PortAI, I can summarize articles.

Mobile-Health Network Solutions pre-market up 31.58%; Inno pre-market up 29.46%; Kala Pharmaceuticals pre-market up 26.60%; Power REIT pre-market up 15.45%; Valneva SE pre-market up 7.55%

Pre-market Hot Trades in US Stocks

Mobile-Health Network Solutions, up 31.58% in pre-market trading, has no significant news recently. The trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Inno, up 29.46% in pre-market trading, has no significant news recently. The trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Top Gainers in Pre-market US Stocks

Kala Pharmaceuticals, up 26.60% in pre-market trading. Based on recent key news:

  1. On November 25, Kala Bio Inc. announced through the EDGAR system that the company's board of directors dismissed Chief Financial Officer Mary Reumuth on November 21 and appointed David Lazar as Chief Executive Officer and Chief Financial Officer. This high-level personnel change is interpreted by the market as a signal of strategic adjustment, driving a significant increase in stock price. The biopharmaceutical industry has been quite volatile recently.

Power REIT, up 15.45% in pre-market trading, has no significant news recently. The trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Valneva SE, up 7.55% in pre-market trading. Based on recent key news:

  1. On November 26, Valneva SE announced that its Lyme disease vaccine candidate VLA15 achieved positive immunogenicity and safety data in Phase 2 studies. This news has enhanced market confidence in the vaccine's success, driving the stock price up.

  2. On November 26, Valneva SE's VLA15 vaccine completed all vaccinations in the VALOR Phase 3 trial, further validating the use of a three-dose vaccination regimen and annual boosters. This progress is seen by the market as a reflection of the company's R&D capabilities, boosting investor confidence.

  3. On November 26, Valneva SE's stock price rose 4.69% in after-hours trading to $9.15, reflecting investors' positive response to the company's vaccine R&D progress. The advancements in vaccine development have energized the biotechnology sector

Source: Tracking Unusual Activity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer